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Background: It is unclear at present whether extracorporeal membrane oxygenation (ECMO) therapy can improve
intestinal mucous barrier function through increased perfusion. The present study establishes an animal model for
post-traumatic acute respiratory distress syndrome (ARDS) and evaluates the effect of v-vECMO treatment on the
intestinal mucosal barrier.
Method: Pulmonary contusion combined with ischemia-reperfusion injury was induced in 30 piglets. The animals
were randomly divided into control, model, and ECMO groups. Serum I-FABP, D-lactate, and endotoxin were
measured over a 24-h period. The jejunum and colon were collected post-mortem and evaluated histopathologically.
The tissue was also examined using electron microscopy, and intestinal tight junction proteins (ZO-1 and occludin)
were measured after 24 h of ECMO therapy. Mortality rate and cause of death were also recorded.
Results: The serum markers evaluating the intestinal mucosal barrier deteriorated in the model group compared to the
control group (p < 0.05). At 2 h, serum I-FABP, D-lactate, and endotoxin were significantly increased in the ECMO group
compared to the model group (p < 0.05). At 12 h, I-FABP and D-lactate in the ECMO group dropped to model group
levels. Serum D-lactate was slightly lower in the ECMO group (p > 0.05) and serum I-FABP was significantly lower than
in the model group (p < 0.05) at 24 h. Similarly, serum endotoxin was slightly lower in the ECMO group than in the
model group (p > 0.05) at 24 h. After 24 h of ECMO therapy, the occludin and ZO-1 protein concentrations in jejunum
and colon mucosa increased moderately compared to that in the model group (p < 0.05). Morphologic structure of the
jejunum and colon did not improved significantly after ECMO therapy. Finally, we observed that ECMO therapy
moderately decreased mortality (25% vs. 50%).
Conclusion: Intestinal mucosal barrier continued to deteriorate in the model group. Although early ECMO therapy
aggravates intestinal mucosal injury, the damage gradually improves later during therapy. The results show that ECMO
therapy has a protective effect on the intestinal mucosal barrier in the later treatment stage.
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Extracorporeal membrane oxygenation (ECMO) is an ef-
fective treatment for patients suffering from severe acute
respiratory distress syndrome (ARDS). When cardiovas-
cular and pulmonary function is impaired, ECMO en-
sures adequate gas exchange and tissue perfusion using
an artificial gas-exchange membrane and blood pumps.
It quickly stabilizes homeostasis, reduces mechanical
ventilation parameters, and offers opportunities for the
diagnosis and treatment of the primary disease [1,2].
ECMO also provides an opportunity for the lung to rest,
thus avoiding iatrogenic ventilator-associated lung injury
[3-5]. The successful use of ECMO in the 2009 H1N1
influenza pandemic brought ECMO into the worldwide
spotlight, and VV-ECMO is being popular [6,7].
The gastrointestinal tract is a driver of multi-organ
dysfunction syndrome (MODS) in critically ill patients
[8]. The intestines receive 20% of cardiac output and
20–35% of systemic oxygen delivery under rest condi-
tions. Unfortunately, blood flow and oxygen supply to
the gastrointestinal tract is reduced under critical con-
ditions to maintain brain and heart perfusion. Some
studies suggest that the pH decreases and causes intes-
tinal mucosal injury when the intestinal oxygen supply
decreases to 50–60% [9,10]. The gastrointestinal bacter-
ial population is an estimated at 1014; when the mucosal
barrier is destroyed, these bacteria translocate across
the intestines into the vasculature, resulting in severe
infection and MODS [8]. In addition, hypoxia disrupts the
bacteria themselves, leading to intestinal flora disorder
[11]. Therefore, quick restoration of intestinal perfusion is
important for the prognosis of critically ill patients. In pa-
tients diagnosed with severe ARDS, ECMO significantly
improves oxygen supply, and Vein-Artery ECMO partially
replaces heart function by increasing blood pressure. The-
oretically, ECMO therapy could improve intestinal muco-
sal barrier function by increasing oxygen and blood
perfusion.
ECMO is a relatively new technology; therefore, fur-
ther research is needed to ascertain its clinical utility.
Our previous studies revealed that ECMO therapy may
injure the heart [12,13], kidney [14], and brain [15].
Other recent case reports show that ECMO therapy can
increase intra-abdominal pressure [16,17]. Notably, one
animal study reported that ECMO therapy may destroy
the intestinal mucosal barrier and increase the incidence
of bacterial translocation [18]. To date, only few case re-
ports have discussed clinical application of ECMO, and no
relevant randomized controlled trials currently exist. Crit-
ically ill patients already have an increased likelihood of el-
evated intra-abdominal pressure and resulting abdominal
compartment syndrome. Therefore, the relationship be-
tween ECMO, abdominal hypertension, and abdominal
compartment syndrome warrants investigation.In a previous animal study, the effects of ECMO
therapy on the intestinal mucosa were not evaluated
under hypoxic or ARDS conditions (ischemia-reperfu-
sion animal models). Mean treatment time for ECMO
was only 8 h, but in clinical practice, ECMO may need
to be administered for a far longer period, making the
study inadequate under present therapeutic guidelines.
Our previous studies of ECMO were performed in
normal healthy animals. Other studies suggest poten-
tial intestinal mucosal damage during ECMO treat-
ment, but these effects were likely related to the
underlying disease rather than being a therapeutic
complication [19,20].
Therefore, the present study, using an ARDS animal
model, investigates whether ECMO therapy adminis-
tered under ARDS conditions improves intestinal mu-
cosal barrier by correcting oxygen delivery and carbon
dioxide removal or instead injures the mucosa.Methods
Animal preparation and group distribution
This study was approved by the Animal Care Committee
of Jingling Hospital. Thirty piglets of either sex weighing
30 ± 5 kg were used. The animals received ketamine
(20 mg/kg IM), diazepam (8 mg/kg IM), and atropine
(0.1 mg/kg IM) prior to anesthetic induction. Then,
ketamine (10–20 mg/kg/h IV) and diazepam (8 mg/kg/
h IV) were administered to maintain anesthesia. Once
anesthetized, each piglet was secured to the surgical
table insulated with a blanket to prevent hypothermia.
The piglets were randomly assigned into either the
control group (n = 6), model group (n = 12), or ECMO
group (n =12).
Catheterization and coagulation monitoring
Once the pigs were anesthetized, tracheotomy was per-
formed and a 6.0-mm internal diameter tracheal tube
was placed immediately. Then, a 16-gauge venous
catheter was placed into the left internal jugular vein
and Lactated Ringer’s solution was administered at
3 mL/kg/h initially. The rate was increased as needed
to maintain the mean arterial pressure above 60 mmHg.
A 16-gauge catheter was inserted into the right femoral
artery to monitor blood pressure. Heparin (150 U/kg
IV) was administered and a 14-French Biomedicus
venous drainage cannula (Medtronic Perfusion Systems,
Minneapolis, MN) was inserted into the right femoral
vein, followed by a 14-French Biomedicus arterial
cannula (Medtronic Perfusion Systems) into the in-
ternal jugular vein for intravenous infusion. Heparin
was infused to maintain the activated clotting time
at 180–220 s. Correct cannula placement was con-
firmed using ultrasonography.
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contusion and ischemia-reperfusion
After the catheters were successfully inserted, subjects in
the model and ECMO groups were positioned laterally.
Adjustable (height and width) smooth cylindrical hollow
columns, measuring 100-cm high and 20 cm in diameter,
were fixed to the vertical surfaces of ribs 6–9. A second
smooth metal cylindrical column (weight 0.45 kg/kg of
pig) was suspended vertically and centrally above the at-
tached columns. The metal column was positioned paral-
lel to the hollow column edge using a rope. The rope was
then cut, which allowed the metal column to free fall and
hit the chest wall of the pig, establishing pulmonary con-
tusion. The procedure was then repeated on the other
lateral side.
After a lung contusion was produced, hemorrhage was
induced through the jugular venous catheter in order to
decrease the mean arterial pressure to 40 ± 5 mmHg
within 10 min; mean arterial pressure was maintained at
this level for 2 h to establish ischemia. Afterwards, in the
first hour, Lactated Ringer’s solution was administered
through the jugular vein at 3 times the blood loss volume,
and 30% of the hemorrhaged blood was administered
through the ear vein. At the second hour, Lactated Ringer’s
solution equal in volume to the hemorrhagic loss was ad-
ministered. At the third hour, reperfusion was established,
and Lactated Ringer’s solution was administered, guided by
PICCO2. The fluid rate was adjusted as needed to maintain
the mean arterial pressure at 90 mmHg.
Experimental protocol
After baseline measurements, animals were randomly di-
vided into three groups: the control group (n = 6), the
model group (n = 12), and the ECMO group (n = 12). Be-
cause of limitations of animal body weight and blood
volume, it is difficult to increase the oxygen supply by
increasing the flow. In our preliminary experiments re-
sults show it is most appropriate at 50 ml/mim/kg for
ECMO circulation. So have no sub groups were divided
according to oxygen concentration in EMO group. At
hour 0, the vascular venous cannula was occluded in the
control and model groups, and the VV-ECMO was estab-
lished in the ECMO group. To measure potential oxida-
tive stress injury associated with the ECMO procedure,
presurgical venous blood samples were collected from the
ear vein. Because the ECMO procedure can be completed
within 1 hour, the initial baseline was set to −1 hour.
VV-ECMO procedure
The ECMO circuit (Quadrox PLS, Maquet, Germany) was
primed with 500 mL of Voluven and 200–300 mL of
Lactated Ringer’s solution. The venovenous-ECMO sys-
tem comprises a centrifugal pump (ROTAFLOW Console,
Maquet, Germany) and a heat exchange (Heater-CoolerUnit HCU 30, Maquet, Germany) maintaining temperature
of 37°C. Sweep gas was 100% oxygen at a flow rate equal to
the blood flow rate (1:1). Blood within the circuit was
drained from the right femoral vein and infused into the
right internal jugular vein at 50 mL/kg/min.
Mechanical ventilation strategy
Once ARDS was established, mechanical ventilation was
begun in a volume-controlled mode with a 0.50 FIO2 and
a 5 mmHg positive end-expiratory pressure. Tidal volume
was 8 mL/kg and respiratory rate was 15 breaths/min.
Sample collection
During ECMO treatment, blood samples were collected
from the right femoral artery at −1, 0, 2, 6, 12, and 24 h.
Samples were centrifuged at 2500 rpm for 15 min at 4°C,
and the plasma was stored at −70°C for measurement of
serum D-lactate, IFBAP, and endotoxin.
At the end of the 24-hour ECMO treatment period, all
animals were euthanized with intravenous potassium
chloride (40 mL, 0.1 g/mL). Jejunum and colon samples,
including mucosal layers, were collected for histopath-
ology, electron microscopy, and intestinal mucosa pro-
tein evaluation.
Examination of sample
Serum intestinal fatty acid-binding protein (I-FABP)
measurement by ELISA
Serum I-FABP was measured at baseline, 0, 2, 6, 12, and
24 h before and during ECMO by spectrophotography
using commercial analysis kits (Sunredbio, USA).
Measurement of D-lactate in serum by
spectrophotography
Serum D-lactate was measured at baseline, 0, 2, 6, 12,
and 24 h before and during ECMO by spectrophotogra-
phy using commercial analysis kits (Abnova, USA).
Serum endotoxin measurement by limulus amebocyte
lysate test
Serum endotoxin was measured using a limulus amebo-
cyte lysate test at baseline, 0, 2, 6, 12, and 24 h before
and during ECMO therapy by chromogenic end point
assay (Limulus Amebocyte Lysate Kit; LAL Test
Company, Xiamen, China).
Measurement of occludin and ZO-1 in intestinal mucosa
by western blot
Western blot analyses were performed to measure occlu-
din and ZO-1 protein expression. Segments of distal
jejunum and colon were excised, and the mucosa was
isolated by scraping. Proteins were extracted using the
RIPA buffer for analysis and protein concentration deter-
mined by bicinchoninic acid assay (Pierce Biochemical).
Figure 1 Effect of ECMO therapy on IFABP in serum in different
time points. Value are ex pressed as mean+/− SD of each group.
Compared with control group, *p < 0.05, compared with Molde
group, #p < 0.05.
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6% SDS–PAGE and electrotransferred onto PVDF mem-
branes (Bio-Rad). The membrane was blocked for
90 min at room temperature in 3% bovine serum albu-
min and 0.1% Tween-20 in Tris-buffered saline (TBS),
followed by overnight incubation with primary antibodies
diluted in 1% bovine serum albumin in TBS at 4°C. Mem-
branes were washed three times in TBS (containing 0.1%
Tween-20) and then incubated with the secondary anti-
bodies for 90 min at room temperature. The membrane
was developed by incubating it for 5 min in Super Signal
Reagent (Pierce). Band intensities were quantified by
densitometry and expressed as the mean area density
using Quantify One software (Bio-Rad), version 4.1.1. For
total protein measurement, mean area density was calcu-
lated relative to GAPDH expression.
Histopathology
Segments of distal jejunum and colon were excised,
transferred into 10% phosphate-buffered saline (PBS)
and buffered formalin, and then embedded in paraffin.
Sections were cut to 5-mm, mounted on glass slides,
and stained with hematoxylin and eosin (H&E). Images
were obtained using a Zeiss Image A1 light microscope
at 100× magnification and AxioVision V4.5 software.
Three pathologists, blinded to the slide identities, evalu-
ated each slide. Histopathology was graded semiquanti-
tatively using the histologic injury scale described by
Chiu et al. [21].
Transmission electron microscopy of tight junctions
Sections of the jejunum and colon (2-mm thick) were
washed and fixed with 4% glutaraldehyde for 2 h and
post-fixed with 1% osmium tetroxide. Tissues were em-
bedded in Epon 812 and thinly sectioned. Thin sections
were cut and stained with uranyl acetate and lead citrate
and examined with an H-600 (Hitachi, Japan) transmis-
sion electron microscope operated at 75 kV.
Statistical analysis
Data were analyzed using SPSS 17.0. Mortality comparison
between the model and ECMO groups was performed
using χ2. Other differences in data were determined using
one-way ANOVA (multiple group pairwise comparison by
LSD test). The p values < 0.05 were considered statistically
significant. Results are presented as mean ± SD.
Results
Mortality and cause of death
4 animals died within 2 h after injury from severe
pneumothorax and bleeding ( chest, heart and liver rup-
ture), as they did not die of mucosal barrier injury they
were discarded from the analysis. In the model group, 6
of 12 pigs (50%) died from multiple causes, includingrefractory hypoxemia (4), hypothermia and coagulation
disorders (1), and congestive heart failure (1). During
ECMO therapy, 3 of 12 pigs (25%) died from two causes:
congestive heart failure (2) and coagulation disorders
and acidosis (1).
ECMO therapy attenuates I-FABP proteins concentrations
in serum for post-traumatic ARDS porcine model
(Figure 1)
I-FABP concentration remained normal in the control
group. After establishing post-traumatic ARDS (0 h), the
I-FABP was significantly higher (p < 0.05) in the model
and ECMO groups than in the control group. I-FABP in-
creased gradually in both the model and ECMO groups;
however, I-FABP in the ECMO group was significantly
higher than in the model group 2 h later, a trend lasting
until 6 h after post-traumatic ARDS (p < 0.05). The
ECMO I-FABP then decreased gradually, equaling the
model group at 12 h (p > 0.05) and declining below the
model group level at 24 h (p < 0.05).
ECMO therapy attenuates D-lactate concentrations in
serum for post-traumatic ARDS porcine model (Figure 2)
D-lactate concentration remained normal in the control
group. After establishing post-traumatic ARDS (hour 0),
the serum D-lactate significantly increased (p < 0.05) in the
model and ECMO groups compared to the control group.
Serum D-lactate increased gradually in both the model and
ECMO groups, but the increase was significantly higher in
the ECMO group at 2 h and until 6 h (p < 0.05) after ARDS
was established. Serum D-lactate then decreased gradually
in the ECMO group, equaling the model group at 12 h
(p > 0.05) and decreasing slightly below the model group
level at 24 h (p > 0.05).
Figure 2 Effect of ECMO therapy on D-Lacate in serum in different
time points. Value are expressed as mean+/− SD of each group.
Compared with control group, *p < 0.05, compared with Model
group, #p < 0.05.
Ni et al. Journal of Cardiothoracic Surgery  (2015) 10:20 Page 5 of 10ECMO therapy attenuates Endotoxin concentrations in
plasma for post-traumatic ARDS porcine model (Figure 3)
Serum endotoxin remained normal in the control group.
Two hours after establishing post-traumatic ARDS, serum
endotoxin in the model and ECMO groups were signifi-
cantly increased compared to the control group (p < 0.05).
Serum endotoxin increased gradually in both the model
and ECMO groups, but the increase was higher in the
ECMO group at 2 h and until 12 h than observed in the
model group (p < 0.05). Serum endotoxin then decreased
gradually in the ECMO group and was slightly lower than
the model group level at 24 h (p > 0.05).Figure 3 Effect of ECMO therapy on endotoxin in serum in
different time points. Value are expressed as mean+/− SD of each
group. compared with control group, *p < 0.05, compared with
Model group, #p < 0.05.ECMO therapy enhances tight junction proteins
concentrations in jejunum and colon for post-traumatic
ARDS porcine model (Figures 4, 5, 6 and 7)
Compared to the control group, the occludin and ZO-1
protein concentrations in jejunum and colon mucosa de-
creased significantly in the model group (p < 0.05). After
24 h, occludin and ZO-1 concentrations moderately in-
creased in the ECMO group compared to the model
group, but this difference was not statistically significant.
ECMO therapy attenuates pathological injury in jejunum
and colon for post-traumatic ARDS porcine model
(Figure 8)
In the control group, subjects had integrated villi and
a compact epithelium. The jejunum and colon in both
the model and ECMO groups had a disordered mucosal
structure, marked atrophy, and blunted villi. In addition,
the brush border was discontinuous and the epithelium
disarrayed. Chiu’s score for the model group was higher
than that for the control group (p < 0.05). At 2 h, the
ECMO group intestinal injury score was not statistically
different from the model group score (p > 0.05).
ECMO therapy attenuates ultra-structure injury in jejunum
and colon for post-traumatic ARDS porcine model
(Figure 9)
Electron microscopy (×50000) showed no significant ab-
normalities in structural integrity of tight junctions and
microvilli in the control group. In the model group, epi-
thelial tight junctions in the jejunum and colon were loos-
ened and the gap widened; there was also microvilli loss,
and desmosomes density decreased. After 24 h of ECMO
therapy, the intestinal mucosal injury was not affected.
Discussion
The present study establishes an post-traumatic ARDS
animal model by inducing chest contusion combined
with ischemia-reperfusion injury. Our preliminary ex-
periment results showed that the PaO2/FIO2 ratio de-
creased to 206.35 ± 18.97, and computer tomography (CT)
examination showed bilateral diffuse caudal pulmonary
dense radio-opacity (data not shown) after traumatizing
the thorax, which confirms that the model was consistent
with ARDS conditions. ARDS can result in systemic organ
hypoxia, and systemic oxygen consumption increases not-
ably under ARDS conditions [22]. Unfortunately, blood
flow and oxygen supply to the gastrointestinal tract de-
creases under critical conditions to maintain perfusion to
vital organs such as brain and heart. The gastrointestinal
tract is a driver of multi-organ dysfunction syndrome
(MODS) in critically ill patients. When exposed to hypoxic
conditions, the intestinal mucosal barrier is destroyed and
bacteria in the gastrointestinal tract translocate into the
blood, resulting in severe infection and progressing to
Figure 4 Tight junction proteins ZO-1 change in jejunum. The protein analysed by western blot with protein levels quantified by
densitometry and normalized to GAPDH. compared with Control group, *p < 0.05.
Figure 5 Tight junction proteins ZO-1 change in colon. The protein analysed by western blot with protein levels quantified by densitometry
and normalized to GAPDH. compared with Control group, *p < 0.05.
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Figure 6 Tight junction proteins Occludin change in jejunum. The protein analysed by western blot with protein levels quantified by
densitometry and normalized to GAPDH. compared with Control group, *p < 0.05.
Figure 7 Tight junction proteins Occludin change in colon. The protein analysed by western blot with protein levels quantified by
densitometry and normalized to GAPDH. compared with Control group, *p < 0.05.
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Figure 8 Histopathologic evaluation (×40) of jejunum and colon by HE staining in ARDS model pigs. Chiu’s scores in jejnum (A1) and
colon (B1) experresed as mean ± SD of the controlgroup, model group, and ECMO group, with *p < 0.05, A2 and B2 represed pathologic
changes in jejunum and colon, respectively.
Figure 9 Ultrastructural change in jejunum and colon using electron mocroscopy.
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66.77% of subjects died from hypoxia under post-
traumatic ARDS conditions. Meanwhile, intestinal mucosa
was continually injured under the hypoxic condition.
Therefore, improving intestinal mucosal oxygen supply
may be an important means to prevent intestinal mucosal
injury and MODS in critically ill patients.
ECMO therapy could improve the prognosis of critical
patients by increasing intestinal tissue oxygen delivery,
which protects the gastrointestinal mucosa barrier.
Thus, we investigated the effect of ECMO treatment on
jejunum and colon mucosa in ARDS model pigs. I-FABP
is a 15KD protein and exists only within the intestinal
epithelium, primarily in the small intestinal microvilli tip
[23]. It is an early and sensitive indicator of intestinal
damage. D-lactate is also a sensitive indicator of intes-
tinal permeability. However, after 2 h of ECMO therapy,
I-FABP, D-lactate, and endotoxin levels were actually
higher in the ECMO group than those observed in
model group subjects. Serum I-FABP and D-lactate
levels remained consistently higher in the ECMO group
than those in model group subjects until 6 h after initiat-
ing ECMO therapy; serum endotoxin remained higher in
the ECMO group than in the model group until 12 h.
These results suggest that ECMO treatment does not
improve the intestinal mucosal barrier, but may actually
severely damage the tissue at 2–12 h post-injury.
An animal study found that ECMO therapy can in-
crease serum I-FABP and D-lactate 1 hour after perfu-
sion injury until a peak at 8 h, which is accompanied by
the destruction of intestinal tight junctions and bacterial
translocation [16]. The intestinal damage was suspected
to be related to an immune inflammatory response dur-
ing early ECMO therapy [16]. Our previous research
suggested that immune mediated inflammation occurs
2 h after initiating ECMO therapy. After 24 h of ECMO
therapy, multiple organs, such as the kidney, brain, and
myocardium, upregulated expression of inflammatory
cytokine [12-14]. In addition, a few rare clinical case re-
ports suggest that ECMO therapy may increase serum
endotoxin [24]. In our clinical experience, bacteremia
may be noted in approximately 50% of patients receiving
ECMO therapy, but after discontinuing ECMO and
extubating the patient, the bacteremia disappears within
24 h, and we suspected that the bacteremia was associ-
ated with a catheter infection.
Despite these findings, the previous studies had several
limitations. Notably, the influence of ECMO therapy on
the intestinal mucosa barrier still needs to be observed
for a longer period mimicking typical clinical conditions.
In the present study, we observed the effect of ECMO
treatment on the intestinal mucosa for an extended
period. After 12 h of ECMO therapy, we found that D-
lactate and I-FABP decreased significantly to modelgroup levels. After 24 h of ECMO therapy, the serum
I-FABP and endotoxin were lower than those observed
in the model group. These findings suggest that early in-
testinal mucosal damage was ameliorated gradually and
continued to improve during an extended period of
ECMO therapy. In contrast, the model group showed
continued mucosal deterioration. We observed that
ECMO therapy can decrease the mortality of post-
traumatic ARDS pigs (ECMO group: 25%; model group:
50%) and potentially eliminate hypoxia-induced mortal-
ity. We speculate that a reduction in intestinal tissue
hypoxia associated with ECMO therapy may offset the
initial immune inflammatory response during therapy.
Long-term intestinal tissue hypoxia causes more serious
adverse effects than the immune inflammatory response
and tissue edema resulting from other factors.
After 24 h of ECMO therapy, all animals were eutha-
nized to evaluate morphology and tight junction proteins
ZO-1 and occludin in the jejunum and colon. In the
Model group, the concentrations of occludin and ZO-1
were decreased significantly, and the morphology was
significantly disordered. After 24 h of ECMO therapy,
there was no morphological evidence of injury to the in-
testinal mucosa in the ECMO group. The occludin and
ZO-1 protein concentrations were increased moderately
in the ECMO group, but there was no statistical difference
between the model and ECMO groups. The hematologic
results suggest significant improvement in injured intes-
tinal mucosa, but the intestinal morphologic structures
did not show these same improvements after 24 h of
ECMO therapy. This discrepancy may reflect a gradual re-
covery of the intestinal mucosa, which may require a lon-
ger time to detect histologically.Limitations
This study uses animal models to mimic ARDS, but the
methodology is not widespread globally. Furthermore,
the lack of morphologic change between the model and
ECMO groups may signal a need for observation over a
longer time.Conclusion
Our study shows that ECMO therapy aggravates intes-
tinal mucosa injury early during therapy, but the injury
declines gradually. Furthermore, ECMO therapy has a
protective effect on the intestinal mucosal barrier in the
later treatment stage. Finally, ECMO therapy decreases
post-traumatic ARDS associated mortality, and may elim-
inate hypoxia-associated mortality. The lack of morpho-
logic change in the intestinal mucosa following ECMO
therapy highlights the need for additional study evaluating
the mucosa over a longer period.
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